Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

NCT04016116 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI left the institution

Conditions

Cancer
Hematological Malignancy

Interventions

DRUG: Pembrolizumab
DRUG: Ruxolitinib

Sponsor

NYU Langone Health